In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

James F. List, Vincent Woo, Enrique Morales et al. · Diabetes Care · 2008 · 696 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Wei Meng, Bruce A. Ellsworth, Alexandra A. Nirschl et al. · Journal of Medicinal Chemistry · 2008 · 628 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.

Y. Kanai, W S Lee, Dennis Brown et al. · Journal of Clinical Investigation · 1994 · 624 citations · Full text

Life Sciences, Molecular Biology, Physiology +15

Chronic Hyperglycemia Triggers Loss of Pancreatic β Cell Differentiation in an Animal Model of Diabetes

Jean‐Christophe Jonas, Arun Sharma, Wendy Hasenkamp et al. · Journal of Biological Chemistry · 1999 · 560 citations · Full text

Life Sciences, Endocrinology, Physiology +17

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

Song‐Ping Han, Deborah Hagan, Joseph R. Taylor et al. · Diabetes · 2008 · 418 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16